Abstract
Drugs may frequently interact adversely to cause drug toxicity or render a needed therapy ineffective. The situation is compounded by the current pattern of drug usage in which approximately ten different drugs are received by the average patient in the hospital. The number of drugs employed in combination in the out-patient setting is also increasing as more chronic diseases are treated for longer periods of time. In this therapeutic milieu, surveys of drug usage have shown that more than 10% of patients were concomitantly receiving drugs considered to interact adversely with one another. This suggests a need not only for an improved awareness of drug interactions by physicians but also for careful investigative documentation of drug interactions and their clinical relevance in man in order to provide a rational education in this important aspect of therapeutics. Mere proliferation of lists containing numerous speculative and inadequately documented drug interactions is educationally counter-productive, serving only to destroy credibility and to cause many physicians to shrug off drug interactions as hobgoblins from the pharmacologist’s imagination.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Aggeler, P.M., O’Reilly, R. A., Leong, L., Kowitz, P.E.: Potentiation of anticoagulant effect of warfarin by phenylbutazone. New Engl. J. Med. 276, 496–501 (1967).
Aggeler, P.M., O’Reilly, R.A.: Effect of heptabarbital on the response to bishydroxy-coumarin in man. J. Lab. clin. Med. 74, 229–238 (1969).
Alexanderson, B.: Pharmacokinetics of nortriptyline in man after single and multiple oral doses: The predictability of steady-state plasma concentrations from single-dose plasma-level data. Europ. J. Clin. Pharmacol. 4, 82–91 (1972).
Alexanderson, B., Borga, O.: Interindividual differences in plasma protein binding of nortriptyline in man — a twin study. Europ. J. Clin. Pharmacol. 4, 196–200 (1972).
Alexanderson, B., Price Evans, D. A., Sjöqvist, F.: Steady-state plasma levels of nortriptyline in twins: Influence of genetic factors and drug therapy. Brit. med. J. 1969 IV, 764–768.
Ambre, J.J., Fischer, L.J.: Effect of coadministration of aluminium and magnesium hydroxides on absorption of anticoagulants in man. Clin. Pharmacol. Ther. 14, 231–237 (1973).
Anders, M.W.: Enhancement and inhibition of drug metabolism. Ann. Rev. Pharmacol. 11, 37–56 (1971).
Arias, I.M., Gartner, L.M., Cohen, M., Ben Ezzer, J., Levi, A.J.: Chronic nonhemolytic unconjugated hyperbilirubinemia with glucuronyl transferase deficiency. Clinical, biochemical, pharmacologic and genetic evidence for heterogeneity. Amer. J. Med. 47, 395–409 (1969).
Avellaneda, M.: Interferencia de los barbituricos en la accion del tromexan. Medicina (Buenes Aires) 15, 109–115 (1955).
Barr, W.H., Adir, J., Garrettson, L.: Decrease of tetracycline absorption in man by sodium bicarbonate. Clin. Pharm. Ther. 12, 779–784 (1971).
Barrowman, J. A., D’Mello, A., Herxheimer, A.: A single dose of neomycin impairs absorption of vitamin A (Retinol) in man. Europ. J. Clin. Pharmacol. 5, 199–202 (1973).
Baylis, E.M., Crowley, J.M., Preece, J.M., Sylvester, P.E., Marks, V.: Influence of folic acid on blood-phenytoin levels. Lancet 1971I, 62–64.
Bazzano, G., Bazzano, G.S.: Digitalis intoxication. Treatment with a new steroid-binding resin. J. Amer. med. Ass. 220, 828–830 (1972).
Benowitz, N., Rowland, M., Forsyth, R., K.L.: Circulatory influences on lidocaine disposition. Clin. Res. 21, 467 (1973).
J., Calimlim, L.R., Morgan, J.P., Dujuvne, C.A., Lasagna, L.: Metabolism and absorption of L-3, 4-dihydroxyphenylalanine in patients with Parkinson’s disease. Ann. N. Y. Acad. Sci. 179, 126–140 (1971).
Binns, T.B.: The absorption of drugs from the alimentary tract, lungs and skin. Brit. J. Hosp. Med. 6, 133–142 (1971).
Black, M., Sherlock, S.: Treatment of Gilbert’s syndrome with phenobarbitone. Lancet 1970 I, 1359–1361.
Bogdanski, D.F., Blaszkowski, T.P., Brodie, B.B.: Effects of enzyme induction on synthesis and catabolism of corticosterone in rats. Analysis by mean of steady-state kinetics. J. Pharmacol, exp. Ther. 179, 372–379 (1971).
Boman, G.: In: Morselli, P.L., Garattini, S., Cohen, S.N. (Eds.): Drug interactions. New York: Raven Press (in press).
Borga, O., Azarnoff, D.L., Forshell, G.P., F.: Plasma protein binding of tricyclic antidepressants in man. Biochem. Pharmacol. 18, 2135–2143 (1969).
Borowitz, J.L., Moore, P.F., Yim, G.K.W., Miya, T.S.: Mechanism of enhanced drug effects produced by dilution of the oral dose. Toxicol, appl. Pharmacol. 19, 164–168 (1971).
Boston Collaborative Drug Surveillance Program: Interaction between chloral hydrate and warfarin. New Engl. J. Med. 286, 53–55 (1972).
Branch, R. A., Herbert, C.M., Read, A. E.: Determinants of serum antipyrine half-lives in patients with liver disease. Gut 14, 569–573 (1973 a).
Branch, R.A., Nies, A. S., Shand, D.G.: The disposition of propranolol. VIII. General implications of the effects of liver blood flow on elimination from the perfused rat liver. Drug Metab. Dispos. 1, 687–690 (1973b).
Branch, R.A., Shand, D.G., Nies, A.S.: Increase in hepatic blood flow and d-propranolol clearance by glucagon in the monkey. J. Pharmacol, exp. Ther. 187, 581–587 (1973 c).
Branch, R. A., Shand, D.G., Wilkinson, G.R., Nies, A. S.: Increased clearance of antipyrine and d-propranolol after phenobarbital treatment in the monkey. J. clin. Invest. 53, 1101–1107 (1974).
Breckenridge, A., Orme, M.: Clinical implications of enzyme induction. Ann. N. Y. Acad. Sci. 179, 421–431 (1971).
Breckenridge, A., Orme, M.,L.E. Davies, L., Thorgeirsson, S.S., Davies, D.S.: Dose-dependent enzyme induction. Clin. Pharmacol. Ther. 14, 514–520 (1973).
Brennan, R.W., Dehejia, H., Kutt, H., Verebely, K., McDowell, F.: Diphenylhydantoin intoxication attendant to slow inactivation of isoniazid. Neurology 20, 687–693 (1970).
Brodie, B.B.: Physico-chemical factors in drug absorption. In: Binns, T.B. (Ed.): Absorption and distribution of drugs, pp. 16–48. Baltimore: Williams and Wilkins 1964.
Brodie, B.B., Chang, C.C., Costa, E.: On the mechanism of action of guanethidine and bretylium. Brit. J. Pharmacol. 25, 171–178 (1965).
Brooks, S.M., Werk, E.E., Ackerman, S.J., Sullivan, I., Thrasher, K.: Adverse effects of phenobarbital on corticosteroid metabolism in patients with bronchial asthma. New Engl. J. Med. 286, 1125–1128 (1972).
Burstein, S., Klaiber, E.L.: Phenobarbital-induced increase in 6 B-hydroxycortisol excretion: clue to its significance in human urine. J. clin. Endocr. 25, 293–296 (1965).
Busfield, D., Child, K.J., Atkinson, R.M., Tomich, E.G.: An effect of phenobarbitone on blood-levels of griseofulvin in man. Lancet 1963 II, 1042–1043.
Caesar, J., Shaldon, S., Cheandussi, L., Guevara, L., Sherlock, S.: The use of indocyanine green in the measurement of hepatic blood flow and as a test of hepatic function. Clin. Sci. 21, 43–57 (1961).
Caldwell, J.H., Bush, C.A., Greenberger, N.J.: Interruption of the enterohepatil circulation of digitoxin by cholestyramine. II. Effect on metabolic disposition of tritium-labeled digitoxin and cardiac systolic intervals in man. J. clin. Invest. 50, 2638–2644 (1971).
Caldwell, J. H., Greenberger, N.J.: Interruption of the enterohepatic circulation of digitoxin by cholestyramine. I. Protection against lethal digitoxin intoxication. J. clin. Invest. 50, 2626–2637 (1971).
Carulli, N., Manenti, F., Gallo, M., Salvioli, G.F.: Alcohol-drug interactions in man: alcohol and tolbutamide. Europ. J. clin. Invest. 1, 421–424 (1971).
Cavalieri, R.R., Suno, L.C., Becker, C.E.: Effects of phenobarbital on thyroxine and triido-thyronine kinetics in Graves’ disease. J. clin. Endocr. 37, 308–316 (1973).
Chaput de Saintonge, D.M., Herxheimer, A.: Sodium bicarbonate enhances the absorption of propantheline in man. Eur. J. Clin. Pharmacol. 5, 239–242 (1973).
Chen, W., Vrindten, P.A., Dayton, P.G., Burns, J.J.: Accelerated aminopyrine metabolism in human subjects pretreated with phenylbutazone. Life Sci. 2, 35–42 (1962).
Cherrick, G.R., Stein, S.W., Leevy, C.M., Davidson, C.S.: Indocyanine green: Observations on its physical properties, plasma decay, and hepatic extraction. J. clin. Invest. 39, 592–600 (1960).
Choi, Y., Thrasher, K., Werk, E.E., jr., Sholiton, L.J., Olinger, C.: Effect of diphenyl-hydantoin on Cortisol kinetics in humans. J. Pharmacol, exp. Ther. 176, 27–34 (1971).
Christensen, L.K., Hansen, J. M., Kristensen, M.: Sulphaphenazole-induced hypoglycaemic attacks in tolbutamide-treated diabetics. Lancet 1963 II, 1298–1310.
Christensen, L.K., Skovsted, L.: Inhibition of drug metabolism by chloramphenicol. Lancet 1969 II, 1397–1399.
Conney, A.H.: Pharmacological implications of microsomal enzyme inductions. Pharmacol. Rev. 19, 317–366 (1967).
Connors, T.A., Cox, P.J., Farmer, P.D., Foster, A.D., Jarman, M.: Some studies on the active intermediate formed in the microsomal metabolism of cyclophosphamide and isophosphamide. Biochem. Pharmacol. 23, 115–129 (1974).
Cooke, A. R., Hunt, J.N.: Absorption of acetylsalicylic acid from unbuffered and buffered gastric contents. Amer. J. dig. Dis. 15, 95–102 (1970).
Corn, M.: Effect of phenobarbital and glutethimide on biological half-life of warfarin. Throm-bos. Diathes. haemorrh. (Stuttg.) 16, 606–612 (1966).
Corn, M., Rookett, J.F.: Inhibition of bishydroxycoumarin activity by phenobarbital. Med. Ann. D. C. 34, 578–579 (1965).
Crigler, J.F., Jr., Gold, N. I.: Sodium phenobarbital-induced decrease in serum bilirubin in an infant with congenital nonhemolytic jaundice and kernicterus. J. clin. Invest. 45, 998–999 (1966).
Crigler, J.F., Jr., Gold, N.I.: Effect of sodium phenobarbital on bilirubin metabolism in an infant with congential, nonhemolytic, unconjugated hyperbilirubinemia, and kernicterus. J. clin. Invest. 48, 42–55 (1969).
Crounse, R.G.: Human pharmacology of griseofulvin. The effect of fat intake on gastrointestinal absorption. J. invest. Dermatol. 37, 529–533 (1961).
Cuoinell, S.A., Conney, A.H., Sansur, M., Burns, J. J.: Drug interactions in man. I. Lowering effect of phenobarbital on plasma levels of bishydroxycoumarin (dicumarol) and diphenylhydantoin (dilantin). Clin. Pharm. Ther. 6, 420–429 (1965).
Cunntngham, M.D., Maoe, J.W., Peters, E.R.: Clinical experience with phenobarbitone in icterus neonatorium. Lancet 1969 I, 550–551.
Curry, S.H.: Relation between binding to plasma protein, apparent volume of distribution, and rate constants of disposition and elimination for chlorpromazine in three species. J. Pharm. Pharmacol. 24, 818–819 (1972).
Curry, S.H., Davis, J.M., Janowsky, D.S., Marshall, J.H.L.: Factors affecting chlorpromazine plasma levels in psychiatric patients. Arch. gen. Psychiat. 22, 209–215 (1970).
Danysz, A., Wisniewski, K.: Control of drug transport through cell membranes. Materia Medica Polona 2, 35–44 (1970).
Davies, J.E., Edmundson, W.F., Carter, C.H., Barqttet, A.: Effect of anticonvulsant drugs on dicophane (D. D. T.) residues in man. Lancet 1969 II, 2–9.
Davis, J.M., Kopin, I. J., Lemberger, L., Axelrod, J.: Effects of urinary pH on amphetamine metabolism. Ann. N. Y. Acad. Sci. 179, 493–501 (1971).
Dayton, P.G., Taroan, Y., Chenkin, T., Weiner, M.: The influence of barbiturates on cou-marin plasma levels and prothrombin response. J. clin. Invest. 40, 1797–1802 (1961).
Drummond, K.H., Hellman, D.A., Marchessault, J.H.V., Feldman, W.: Cyclophosphamide in the nephrotic syndrome of childhood. Canad. Med. Ass. J. 98, 524–531 (1968).
Evans, G.H., Nies, A.S., Shand, D.G.: The disposition of propranolol. III. Decreased half-life and volume of distribution as a result of plasma binding in man, monkey, dog and rat. J. Pharmacol. exp. Ther. 186, 114–122 (1973).
Faloon, W.W.: Drug production of intestinal malabsorption. N. Y. State J. Med. 70, 2189 – 2192 (1970).
Fann, W.E., Kaumann, J.S., Griffith, J.D., Davis, J.M., Janowsky, D.S., Oates, J.A.: Doxepin: Effects on transport of biogenic amines. Psychopharmacologica (Berl.) 22, 111–125 (1971a).
Fann, W.E., Davis, J.M., Janowsky, D.S., Oates, J.A.: Chlorpromazine reversal of the antihypertensive action of guanethidine. Lancet 1971IIb, 436–437.
Field, J.B., Ohta, M., Boyle, C., Bemer, A.: Potentiation of acetohexamide hypoglycemia by phenylbutazone. New Engl. J. Med. 277, 889–894 (1967)
Forrest, F.M., Forrest, I.S., Serra, M.T.: Modification of chlorpromazine metabolism by some other drugs frequently administered to psychiatric patients. Biol. Psych. 2, 53–58 (1970).
Garrettson, L.K., Perel, J.M., Dayton, P.G.: Methylphenidate interaction with both anticonvulsants and ethyl biscoumacetate. J. Amer. med. Ass. 207, 2053–2056 (1969).
George, C.F., Fenyvesi, T., Conolly, M.E., Dollery, C.T.: Pharmacokinetics of dextro-, laevo-, and racemic propranolol in man. Europ. J. clin. Pharmacol. 4, 74–76 (1972).
Gerhardt, R.E., Knouss, R.P., Thyrum, P.T., Lfohi, R.J., Morris, J.J.: Quinidine excretion in aciduria and alkaluria. Ann. intern. Med. 71, 927–933 (1969).
Gibaldi, M., Grundhofer, B.: Enhancement of intestinal absorption of a quaternary ammonium compound by salicylate and trichloroacetate. J. pharm. Sci. 62, 343–344 (1973).
Gibaldi, M., Boyes, R.N., Feldman, S.: Influence of first-pass effect on availability of drugs on oral administration. J. Pharm. Sci. 60, 1338–1340 (1971).
Gillette, J. R.: Factors affecting drug metabolism. Ann. N. Y. Acad. Sci. 179, 43–66 (1971).
Gillette, J. R.: Overview of drug-protein binding. Ann. N. Y. Acad. Sci. 226, 6–17 (1973).
Gillette, J.R., Mitchell, J.R.: Drug actions and interactions: theoretical considerations (this volume).
Goldstein, A., Aronow, L., Kalman, S. M.: Principles of drug action: The basis of pharmacology. New York: Hoeber Medical Division, Harper and Row 1968.
Goss, J. E., Dickhaus, D.W.: Increased bishydroxycoumarin requirements in patients receiving phenobarbital. New Engl. J. Med. 273, 1094–1095 (1965).
Gram, L.F., Overo, K.F.: Drug interaction: Inhibitory effect of neuroleptics on metabolism of tricyclic antidepressants in man. Brit. med. J. 1972I, 463–465 (1972).
Griner, P.F., Raisz, L.G., Riokles, F.R., Wiesner, P.J., Odoroff, C.L.: Chloral hydrate and warfarin interaction: clinical significance. Ann. intern. Med. 74, 540–543 (1971).
Hague, D.E., Smith, M.E., Ryan, J.R., MoMahon, F.G.: The effect of methylphenidate and prolintane on the metabolism of ethyl biscoumacetate. Clin. Pharmacol. Ther. 12, 259–262 (1971).
Hahn, K.-J., Eiden, W., Schettle, M., Hahn, M., Walter, E., Weber, E.: Effect of cholestyramine on the gastrointestinal absorption of phenprocoumon and acetylosalicylic acid in man. Europ. J. Clin. Pharmacol. 4, 142–145 (1972).
Hahn, T.J., Birge, S.J., Scharp, C.R., Avioli, L.V.: Phenobarbital-induced alterations in vitamin D metabolism. J. Clin. Invest. 51, 741–748 (1972).
Hahn, T. J.: Anticonvulsant therapy and vitamin D. Ann. intern. Med. 78, 308–309 (1973).
Hansen, J.M., Kristensen, M., Skovsted, L., Christensen, L.K.: Dicoumarol induced diphenylhydantoin intoxication. Lancet 1966 II, 265–266.
Hansen, J. M., Kristensen, M., Skovsted, L.: Sulthiame (Ospolot®) as inhibitor of diphenylhydantoin metabolism. Epilepsia 9, 17–22 (1968).
Hansen, J. M., Siersbaek-Nielsen, K., Skovsted, L.: Carbamazepine-induced acceleration of diphenylhydantoin and warfarin metabolism in man. Clin. Pharmacol. Ther 12, 539–543 (1971).
Harris, R.C., Lucey, J.F., MaoLean, J.R.: Kernicterus in premature infants associated with low concentrations of bilirubin in the plasma. Pediatrics 21, 875–884 (1958).
Heading, R.C., Nimmo, J., Prescott, L.F., Tqthtll, P.: The dependence of paracetamol absorption on the rate of gartric emptying. Brit. J. Pharmacol. 47, 415–421 (1973).
Hollister, L., Levy, G.: Some aspects of salicylate distribution and metabolism in man. J. Pharm. Sci. 54, 1126–1129 (1965).
Hunninghake, D.B., Azarnoff, D.L.: Drug interactions with warfarin. Arch. int. Med. 121, 349–352 (1968).
Hunter, J., Maxwell, J. D., Carrella, M., Stewart, D. A., Williams, R.: Urinary D-glucaric-acid excretion as a test for hepatic enzyme induction in man. Lancet 1971I 572–575.
Huwitz, A.: In: Morselli, P.L., Garattini, S., Cohen, S.N. (Eds.): Drug interactions. Raven Press (in press).
Jao, J.W., Jusko, W.J., Cohen, J.L.: Phenobarbital effects on cyclophosphamide pharmacokinetics in man. Cancer Res. 32, 2761–2764 (1972).
Johnson, L., Sarmiento, F., Blanc, W.A., Day, R.: Kernicterus in rats with an inherited deficiency of glucuronyl transferase. J. Dis. Child. 79, 591–608 (1959).
Jubiz, W., Levinson, R.A., Meikle, A.W., West, C.D., Tyler, P.H.: Absorption and conjugation of metyrapone during diphenylhydantoin therapy: Mechanism of the abnormal response to oral metyrapone. Endocrinology 86, 328–331 (1970).
Kater, R.M., Roggin, G., Tobon, F., Zieve, P., Iber, F. L.: Increased rate of clearance of drugs from the circulation of alcoholics. Amer. J. med. Sci. 258, 35–39 (1969).
Keen, P.: Effect of binding to plasma proteins on the distribution, activity, and elimination of drugs. In: Brodie, B.B., Gillette, J.R. (Eds.): Handbook of experimental pharmacology, Vol. XXVIII, Part I, Chapter 10. Berlin-Heidelberg-New York: Springer 1971.
Kekki, M., Pyörälä, K., Mustala, O., Salmi, H., Jussila, J., Srurala, M.: Multi-compartment analysis of the absorption kinetics of warfarin from the stomach and small intestine. Int. J. clin. Pharmacol. 2, 209–211 (1971).
Kiørboe, E.: Phenytoin intoxication during treatment with Antabuse (disulfiram). Epilepsia 7, 246–249 (1966).
Koch-Weser, J., Sellers, E.M.: Drug interactions with coumarin anticoagulants. New Engl. J. Med. 285, 478–498 (1971).
Kojima, S., Smith, R.B., Doluisio, J.T.: Drug absorption. V. Influence of food on oral absorption of phenobarbital in rats. J. pharm. Sci. 60, 1639–1641 (1971).
Kolmodin, B., Azarnofp, D.L., Sjoquist, F.: Effect of environmental factors on drug metabolism: Decreased plasma half-life of antipyrine in workers exposed to chlorinated hydrocarbon insecticides. Clin. Pharmacol. Ther. 10, 638–642 (1969).
Kolmodin-Hedman, B.: Decreased plasma half-life of phenylbutazone in workers exposed to chlorinated pesticides. Europ. J. Clin. Pharmacol. 5, 195–198 (1973).
Kristensen, J., Hansen, J.M.: Accumulation of chlorpropamide caused by dicoumarol. Acta med. scand. 183, 83–86 (1968).
Kristensen, M., Hansen, J. M., Skovsted, L.: The influence of phenobarbital on the half-life of diphenylhydantoin in man. Acta med. scand. 185, 347–350 (1969).
Kunin, C.M.: Clinical pharmacology of the new penicillins. II. Effect of drug which interfere with binding to serum proteins. Clin. Pharmacol. Ther. 7, 180–188 (1966).
Kuntzman, R.: Drugs and enzyme induction. Ann. Rev. Pharmacol. 9, 21–36 (1969).
Kupferberg, H. J., Jeffery, W., Hunninghake, D.B.: Effect of methylphenidate on plasma anticonvulsant levels. Clin. Pharmacol. Ther. 13, 201–204 (1972).
Kutt, H., Haynes, J., Verebely, K., McDowell, F.: The effect of phenobarbital on plasma diphenylhydantoin level and metabolism in man and in rat liver microsomes. Neurology 19, 611–616 (1969).
Kutt, H., Winters, W., McDowell, F.H.: Depression of parahydroxylation of diphenylhydantoin by antituberculosis chemotherapy. Neurology 16, 594–602 (1966).
Kutt, H., Brennan, R., Dehejia, H., Verebely, K.: Diphenylhydantoin intoxication. A complication of isoniazid therapy. Amer. Rev. resp. Dis. 101, 377–384 (1970).
Latham, A.M., Millbank, L., Richens, A., Rowe, D.J.F.: Liver enzyme induction by anticonvulsant drugs, and its relationship to disturbed calcium and folic acid metabolism. J. clin. Pharmacol. 13, 337–342 (1973).
Laurence, D.R., Rosenheim, M. L.: Clinical effects of drugs which prevent the release of adrenergic transmitter. In: Vane, J.R., Wolstenholme, G.E.W., O’Connor, M. (Eds.): Adrenergic mechanisms, pp. 201–208. Boston: Little, Brown 1960.
Leishman, A. W. D., Matthews, H. L., Smith, A. J.: Antagonism of guanethidine by imipramine. Lancet 1963 I, 112.
Levi, A., Sherlock, S., Walker, D.: Phenylbutazone and isoniazid metabolism in patients with liver disease in relation to previous drug therapy. Lancet 1968I, 1275–1279.
Levine, R.R.: Factors affecting gastrointestinal absorption of drugs. Digest. Dis. 15, 171–188 (1970).
Levy, G., Rao, B.K.: Enhanced intestinal absorption of riboflavin from sodium alginate solution in man. J. Pharm. Sci. 61, 279–280 (1972).
Levy, G., O’Reilly, R. A., Aggeler, P.M., Keech, G.M.: Pharmacokinetic analysis of the anticoagulant action of warfarin in man. Clin. Pharmacol. Ther. 11, 372–377 (1970).
Levy, G., Gibaldi, M., Procknal, J. A.: Effect of an anticholinergic agent on riboflavin absorption in man. J. pharm. Sci. 61, 798–799 (1972).
Liegler, D. G., Henderson, E. S., Hahn, M. A., Oltverio, V.T.: The effect of organic acids on renal clearance of methotrexate in man. Clin. Pharmacol. Ther. 10, 849–857 (1969).
Lipsett, M.B.: Factors influencing the rate of metabolism of steroid hormones in man. Ann. N. Y. Acad. Sci. 179, 442–449 (1971).
MaoDonald, M.G., Robinson, D.S.: Clinical observations of possible barbiturate interference with anticoagulation. J. Amer. med. An. 204, 97–100 (1968).
MaoDonald, M.G., Robinson, D.S., Sylwester, D., Jaffe, J.J.: The effects of phenobarbital, chloral betaine, and glutethimide administration on warfarin plasma levels and hypo-prothrombinemic responses in man. Clin. Pharmacol. Ther. 10, 80–84 (1969).
Magnussen, M.P.: The effect of ethanol on the gastrointestinal absorption of drugs in the rat. Acta Pharmacol. (Kbh.) 26, 130–144 (1968).
Manninen, V., Apajalahti, A., Melin, J., Karesoja, M.: Altered absorption of digoxin in patients given propantheline and meteclopramide. Lancet 1973I, 398–401.
Maxwell, J. D., Hunter, J., Stewart, D.A., Ardeman, S., Williams, R.: Folate deficiency after anticonvulsant drugs: An effect of hepatic enzyme induction ? Brit. med. J. 1972I, 297–299.
McMullin, G.P.: Phenobarbitone and neonatal jaundice. Lancet 1968 II, 978–979.
McMullin, G.P., Hayes, M.F., Arora, S.C.: Phenobarbitone in rhesus haemolytic disease. Lancet 1970 II, 949–952.
McQueen, E.G., Owen, D., Ferry, D.G.: Effect of phenytoin and other drugs in reducing serum DDT levels. N. Z. med. J. 75, 208–211 (1972).
Meikle, A.W., Jubiz, W., Matsukura, S., West, C.D., Tyler, F.H.: Effect of diphenylhy-dantoin on the metabolism of metyrapone and release of ACTH in man. J. clin. Endocr. 29, 1553–1558 (1969).
Meyer, J.F., McAllister, C.K., Goldberg, L.I.: Insidious and prolonged antagonism of guanethidine by amitriptyline. J. Amer. med. Ass. 213, 1478–1488 (1970).
Mitchell, J. R., Arias, L., Oates, J.A.: Antagonism of the antihypertensive action of guanethidine sulfate by desipramine hydrochloride. J. Amer. med. Ass. 202. 973–976 (1967).
Mitchell, J. R., Cavanaugh, J.H., Arias, L., Oates, J.A.: Guanethidine and related agents. III. Antagonism by drugs which inhibit the norepinephrine pump in man. J. clin. Invest. 49, 1596–1604 (1970).
Mitchell, J. R., Oates, J.A.: Guanethidine and related agents. I. Mechanism of the selective blockade of adrenergic neurons and its antagonism by drugs. J. Pharmacol, exp. Ther. 172, 100–107 (1970).
Mitchell, J. R., Potter, W.Z., Hinson, J.A., Snodgrass, W.R., Timbrell, J.A., Gillette, J. R.: Toxic drug reactions (this volume).
Morselli, P.L., Rizzo, M., Garattini, S.: Interaction between phenobarbital and diphenyl-hydantoin in animals and in epileptic patients. Ann. N. Y. Acad. Sci. 179, 88–107 (1971).
Neuvonen, P.J., Gothoni, G., Hackman, R., Bjorksten, K.: Interference of iron with the absorption of tetracyclines in man. Brit. med. J. 1970IV, 532–534.
Nies, A. S., Evans, G.H., Shand, D.G.: The hemodynamic effects of beta adrenergic blockade on the flow-dependent hepatic clearance of propranolol. J. Pharm, exp. Ther. 184, 716–720 (1973).
Nies, A.S., Oates, J. A.: Clinicopathologic conference: Hypertension and the lupus syndrome-revisited. Amer. J. Med. 51, 812–814 (1971).
Oates, J.A., Mitchell, J.R., Feagin, O.T., Kaupmann, J.S., Shand, D.G.: Distribution of guanidinium antihypertensives-mechanism of their selective action. Ann. N. Y. Acad. Sci. 179, 302–308 (1971).
Odell, G.B.: Studies in kernicterus. I. The protein binding of bilirubin. J. clin. Invest. 38, 823–833 (1959).
Ohnhaus, E.E., Thorgeirsson, S.S., Davies, D.S., Breckenridge, A.: Changes in liver blood flow during enzyme induction. Biochem. Pharmacol. 20, 2561–2570 (1971).
Olesen, O. V.: The influence of disulfiram and calcium carbimide on the serum diphenylhy-dantoin. Arch. Neurol. 16, 642–644 (1967).
O’Malley, K., Browning, M., Stevenson, I., Turnbull, M. J.: Stimulation of drug metabolism in man by tricyclic antidepressants. Europ. J. clin. Pharmacol. 6, 102–106 (1973).
O’Reilly, R.A.: Potentiation of anticoagulant effect by disulfiram (antabuse). Clin. Res. 19, 180 (1971).
O’Reilly, R. A., Aggeler, P.M.: Phenylbutazone potentiation of anticoagulant effect. Fluo-rometric assay of warfarin. Proc. exp. Biol. (N. Y.) 128, 1080–1083 (1968).
O’Reilly, R.A., Sahud, M.A., Robinson, A.J.: Studies on the interaction of warfarin and Clofibrate in man. Thrombos. Diathes. haemorrh. (Stuttg.) 27, 309–318 (1972).
Pettinger, W.A., Oates, J.A.: Supersensitivity to tyramine during monoamine oxidase inhibition in man. Clin. Pharmacol. Ther. 9, 341–344 (1968).
Plaoe, V.A., Benson, H.: Dietary influences on therapy with drugs. J. Mond. Pharm. 14, 261–278 (1971).
Pouoher, R.L., Vecohio, T.J.: Absence of tolbutamide effect on anticoagulant therapy. J. Amer. med. Ass. 197, 1069–1070 (1966).
Ramboer, C., Thompson, R.P.H., Williams, R.: Controlled trials of phenobarbitone therapy in neonatal jaundice. Lancet 1969 I, 966–968.
Rand, M. J., Trinker, F.R.: The mechanism of the augmentation of responses to indirectly acting sympathomimetic amines by monoamine oxidase inhibitors. Brit. J. Pharmacol. 33, 287–303 (1968).
Reidenberg, M.M., Affrime, M.: Influence of disease on binding of drugs to plasma proteins. Ann. N. Y. Acad. Sci. 226, 115–126 (1973).
Reyes, H., Levi, J. A., Levine, R., Gatmattan, Z., Arias, I.M.: Bilirubin: a model for drug metabolism studies in man. Ann. N. Y. Acad. Sci. 179, 520–528 (1971).
Reynolds, E.H.: Diphenylhydantoin: Hematologic aspects of toxicity. In: Woodbury, D.M., Penry, J.K., Schmidt, R.P. (Eds.): Antiepileptic drugs, Chapter 23, pp. 247–262. New York: Raven Press 1972.
Riegelman, S., Rowland, M., Epstein, W.L.: Griseofulvin-phenobarbital interaction in man. J. Amer. med. Ass. 213, 426–431 (1970).
Rivera-Calimlim, L.: Effect of chronic drug treatment on intestinal membrane transport of 14-C-Z-dopa. Brit, J. Pharmacol. 46, 708–713 (1972).
Robinson, D.S., Benjamin, D.M., McCormack, J.J.: Interaction of warfarin and non-systemic gastrointestinal drugs. Clin. Pharmacol. Ther. 12, 491–495 (1970).
Robinson, D.S., MacDonald, M.G.: The effect of phenobarbital administration on the control of coagulation achieved during warfarin therapy in man. J. Pharmacol. exp. Ther. 153, 250–253 (1966).
Rothstein, E.: Warfarin effect enhanced by disulfiram. J. Amer. med. Ass. 206, 1574–1575 (1968).
Rowland, M.: Influence of route of administration on drug availability. J. pharm. Sci. 61, 70–74 (1972).
Rowland, M., Benet, L.Z., Graham, G.G.: Clearance concepts in pharmacokinetics. J. Pharmacokin. Biopharm. 1, 123–136 (1973).
Samuel, P., Waithe, W.I.: Reduction of serum cholesterol concentrations by neomycin, paraaminosalicylic acid, and other antibacterial drugs in man. Circulation 24, 578–591 (1961).
Scheiner, J., Altemeier, W.A.: Experimental study of factors inhibiting absorption and effective therapeutic levels of declomycin. Surg. Gynec. Obstet. 114, 9–14 (1962).
Scheline, R.R.: Metabolism of foreign compounds by gastrointestinal microorganisms. Pharmacol. Rev. 25, 451–532 (1973).
Schrogie, J.J., Solomon, H.M.: The anticoagulant response to bishydroxycoumarin. II. The effect of D-thyroxine, Clofibrate, and norethandrolone. Clin. Pharm. Ther. 8, 70–77 (1967).
Sellers, E.M., Lang, M., Koch-Weser, J., LeBlano, E., Kalant, H.: Interaction of chloral hydrate and ethanol in man. I. Metabolism. Clin. Pharmacol. Ther. 13, 37–49 (1972a).
Sellers, E.M., Carr, G., Bernstein, J. G., Sellers, S., Kooh-Weser, J.: Interaction of chloral hydrate and ethanol in man. II. Hemodynamics and performance. Clin. Pharmacol. Ther. 13, 50–58 (1972b).
Sellers, E.M., Koch-Weser, J.: Potentiation of warfarin-induced hypoprothrombinemia by chloral hydrate. New Engl. J. Med. 283, 827–831 (1970).
Silverman, W.A., Andersen, D.H., Blano, W.A., Crozier, D.N.: A difference in mortality rate and incidence of kernicterus among premature infants allotted to two prophylactic antibacterial regimens. Pediatrics 18, 614–625 (1956).
SiuRala, M., Mustala, O., Jussila, J.: Absorption of acetylsalicylic acid by a normal and an atrophic gastric mucosa. Scand. J. Gastroenterol. 4, 269–273 (1969).
Sjöqvist, F., Berglund, F., Borga, O., Hammer, W., Andersson, S., Thorstrand, C.: The pH-dependent excretion of monomethylated tricyclic antidepressants. Clin Pharmacol. Ther. 10, 826–833 (1969).
Smih, C.B.: The role of monoamine oxidase in the intraneuronal metabolism of noradrenalin released by indirectly acting sympathomimetic amines or by adrenergic nerve stimulation J. Pharmacol, exp. Ther. 151, 207–220 (1966).
Solomon, H.M., Abrams, W. B.: Interactions between digitoxin and other drugs in man. Amer. Heart J. 83, 277–280 (1972).
Solomon, H.M., Sohrogie, J. J.: The effect of phenyramidol on the metabolism of bishydroxy-coumarin. J. Pharmacol, exp. Ther. 154, 660–666 (1966).
Solomon, H.M., Sohrogie, J.J.: Effect of phenyramidol and bishydroxycoumarin on the metabolism of tolbutamide in human subjects. Metabolism 16, 1029–1033 (1967).
Solomon, H.M., Schrogie, J.J., Williams, D.: The displacement of phenylbutazone-14C and warfarin-14C from human albumin by various drugs and fatty acids. Biochem. Pharmacol. 17, 143–151 (1968).
Solomon, H.M., Reich, S., Spirt, N., Abrams, W.B.: Interactions between digitoxin and other drugs in vitro and in vivo. Ann. N. Y. Acad. Sci. 179, 362–369 (1971).
Stenson, R.E., Constantino, R. T., Harrison, D.C.: Interrelationships of hepatic blood flow, cardiac output, and blood levels of lidocaine in man. Circulation 43, 205–211 (1971).
Thompson, G.R.: Inhibitory effect of neomycin on cholesterol absorption in germ-free pigs. Gut 11, 1063 (1970).
Thompson, G.R., Barrowman, J., Gutierrez, L.: Action of neomycin on the intralumen phase of lipid absorption. J. clin. Invest. 50, 319–323 (1971).
Thomson, P.D., Rowland, M., Melmon, K.L.: The influence of heart failure, liver disease, and renal failure on the disposition of lidocaine in man. Amer. Heart J. 82, 417–421 (1971).
Toskes, P.P., Deren, J. J.: Selective inhibition of vitamin B12 absorption by para-aminosal-icylic acid. Gastroenterology 62, 1232–1237 (1972).
Trinker, F.R., Rand, M.J.: The effect of nialamide, pargyline, and tranylcypromine on the removal of amphetamine by the perfused liver. J. Pharm. Pharmacol. 22, 496–499 (1970).
Trolle, D.: Phenobarbitone and neonatal icterus. Lancet 1, 251–252 (1968a).
Trolle, D.: Decrease of total serum-bilirubin concentration in newborn infants after phenobarbitone treatment. Lancet 1968 II, 705–708.
Udall, J.A.: Letter to editor regarding Chloral hydrate and warfarin therapy. Ann. intern. Med. 75, 141–142 (1971).
Vesell, E.S., Page, J. G.: Genetic control of the phenobarbital-induced shortening of plasma antipyrine half-lives in man. J. clin. Invest. 48, 2202–2209 (1969).
Vesell, E.S., Page, J. G., Passananti, G.T.: Genetic and environmental factors affecting ethanol metabolism in man. Clin. Pharmacol. Ther. 12, 192–201 (1971).
Vesell, E.S., Passananti, G.T., Greene, F.E.: Impairment of drug metabolism in man by allopurinol and nortriptyline. New Engl. J. Med. 283, 1484–1488 (1970).
Wardell, W.: In: Morselli, P.L., Garattini, S., Cohen, S.N. (Eds.): Drug interactions. New York: Raven Press (in press).
Webb, D.I., Chodos, R.B., Mahar, C.Q., Faloon, W.W.: Mechanism of vitamin B12 malabsorption in patients receiving colchicine. New Engl. J. Med. 279, 845–850 (1968).
Weloh, R.M., Harrison, Y.E., Conney, A.H., Burns, J.J.: An experimental model in dogs for studying interactions of drugs with bishydroxycoumarin. Clin. Pharmacol. Therap. 10, 817–825 (1969).
Weloh, R.M., Harrison, Y.E., Gommi, B.W., Poppers, P.J., Finster, M., Conney, A.H.: Stimulatory effect of cigarette smoking on the hydroxylation of 3, 4-benzpyrene and the N-demethylation of 3-methyl-4-monomethylaminoazobenzene by enzymes in human placenta. Clin. Pharmacol. Ther. 10, 100–109 (1969).
Werk, E.E., Jr., MaoGee, J., Sholiton, L.J.: Effect of diphenylhydantoin on Cortisol metabolism in man. J. clin. Invest. 43, 1824–1835 (1964).
Werk, E.E., Jr., Thrasher, K., Sholiton, L.J., Olinger, C., Choi, Y.: Cortisol production in epileptic patients treated with diphenylhydantoin. Clin. Pharmacol. Ther. 12, 698–703 (1971).
Wilson, J.T.: Developmental pharmacology: a review of its application to clinical and basic science. Ann. Rev. Pharmacol. 12, 423–450 (1972).
Winkler, K., Keiding, S., Tygstrup, N.: Clearance as a guantitative measure of liver function. In: Baumgartner, G., Preisig, R. (Eds.): The liver: quantitative aspects of structure and function, pp. 144–155. Basel: S. Karger 1973.
Yaffe, S.J., Levy, G., Matsuzawa, T., Baliah, T.: Enhancement of glucuronide conjugating capacity in a hyperbilirubinemic infant due to apparent enzyme induction by phenobarbital. New Engl. J. Med. 275, 1461–1465 (1966).
Yeung, C.Y., Field, C.E.: Phenobarbitone therapy in neonatal hyperbilirubinaemia. Lancet 1969 II, 135–139.
Zubrod, C.G., Kennedy, T.J., Shannon, J.A.: Studies on the chemotherapy of the human malarias. VIII. The physiological disposition of pamaquine. J. Clin. Invest. 27: Symposium on Malaria, pp. 114–120 (1948).
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1975 Springer-Verlag Berlin · Heidelberg
About this chapter
Cite this chapter
Shand, D.G., Mitchell, J.R., Oates, J.A. (1975). Pharmacokinetic Drug Interactions. In: Gillette, J.R., Mitchell, J.R. (eds) Concepts in Biochemical Pharmacology. Handbuch der experimentellen Pharmakologie / Handbook of Experimental Pharmacology, vol 28 / 3. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-46314-3_11
Download citation
DOI: https://doi.org/10.1007/978-3-642-46314-3_11
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-46316-7
Online ISBN: 978-3-642-46314-3
eBook Packages: Springer Book Archive